• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates

Edwards Lifesciences

Edwards Lifesciences shares fall on Street-beating Q1 results

April 26, 2022 By Jim Hammerand

Edwards Lifesciences (NYSE: EW) posted first-quarter results today that beat the consensus forecast on Wall Street. It also reaffirmed its outlook for the rest of the year, with CEO Michael Mussallem saying, “We are hopeful the worst of the pandemic is behind us.” The Irvine, California–based cardio device company reported profits of $373.6 million, or […]

Filed Under: Blog, Business/Financial News, Cardiovascular, Featured, MassDevice Earnings Roundup, News Well, Replacement Heart Valves, Structural Heart, Wall Street Beat Tagged With: BTIG, Edwards Lifesciences, Michael Mussallem

FDA approves Edwards Lifesciences’ tissue-based mitral valve replacement

March 31, 2022 By Sean Whooley

Edwards Lifesciences (NYSE:EW) announced today that the FDA approved its Mitris Resilia tissue valve replacement system. Irvine, California-based Edwards designed the Mitris Resilia valve with a saddle-shaped sewing cuff that mimics the asymmetric shape of the native mitral valve. In addition, it features a low-profile frame for avoiding obstruction of the left ventricular outflow tract […]

Filed Under: Cardiac Implants, Cardiovascular, Featured, Food & Drug Administration (FDA), Implants, News Well, Regulatory/Compliance, Replacement Heart Valves, Structural Heart Tagged With: Edwards Lifesciences, FDA

These 10 medtech companies’ stocks performed best in 2021

March 7, 2022 By Sean Whooley

Following a year like no other in 2020, 2021 was when many looked to rebound — including the medtech industry. A number of medtech companies followed up a challenging, pandemic-enveloped year with impressive performances. Plenty of them had already proven in 2020 that they were capable of a quick bounce-back. Here are 10 medtech companies […]

Filed Under: Business/Financial News, Cardiovascular, Diabetes, Featured, News Well, Orthopedics, Wall Street Beat Tagged With: Abbott, Abiomed, atricure, Bio-Rad, Dexcom, Edwards Lifesciences, ICU Medical, Inspire Medical Systems Inc., ResMed, Stryker

Edwards Lifesciences misses on Q4 earnings as omicron hammers hospitals

January 27, 2022 By Jim Hammerand

Edwards Lifesciences (NYSE:EW) posted fourth-quarter results that fell short of the consensus forecast on Wall Street, but reaffirmed its outlook for 2022. The Irvine, California-based heart device company yesterday evening reported profits of $335.3 million — or $0.53 per diluted share — on sales of $1.33 billion for the three months ended Dec. 31, 2021, […]

Filed Under: Business/Financial News, Cardiovascular, Featured, MassDevice Earnings Roundup, News Well, Replacement Heart Valves, Wall Street Beat Tagged With: Edwards Lifesciences

FDA approves Edwards Lifesciences Sapien 3 with Alterra for pulmonary regurgitation

December 20, 2021 By Sean Whooley

Edwards Lifesciences (NYSE:EW) announced today that it received FDA approval for the use of its Sapien 3 transcatheter valve with the Alterra adaptive prestent. Irvine, California-based Edwards garnered the FDA nod for use of the Sapien 3 with Alterra for patients with severe pulmonary regurgitation. The Sapien 3 transcatheter pulmonary valve (TPV) system combines the […]

Filed Under: Cardiac Implants, Cardiovascular, Featured, Food & Drug Administration (FDA), Regulatory/Compliance, Replacement Heart Valves, Stents, Structural Heart Tagged With: Edwards Lifesciences, FDA, tavr

Baxter, 3M, Abbott near the top of Newsweek’s most responsible companies list

December 3, 2021 By Sean Whooley

Several medtech, healthcare and life sciences companies, including big names like Abbott (NYSE:ABT), 3M (NYSE:MMM) and Baxter (NYSE:BAX), are among the 500 “most responsible,” according to Newsweek. The outlet published its “America’s Most Responsible Companies 2022” list, marking the third installment of the compilation (in partnership with Statista), this time expanded to include 500 of […]

Filed Under: Business/Financial News, Featured, News Well Tagged With: 3m, Abbott, Amerisource Bergen, Avanos Medical (formerly Halyard Health), Baxter, BD, Biogen, Boston Scientific, Cantel Medical Corp., Cardinal Health, Edwards Lifesciences, Gilead Sciences, Henry Schein, Hillrom, Hologic, Illumina Inc., Insulet, LabCorp, Merck, Pfizer, Quest Diagnostics Inc., ResMed, Thermo Fisher Scientific, Varex Imaging, Varian Medical Systems

Edwards touts trial results for Evoque transcatheter tricuspid valve replacement system

November 8, 2021 By Sean Whooley

Edwards Lifesciences (NYSE:EW) shared data from a clinical trial showing that its Evoque transcatheter tricuspid valve replacement offers favorable patient outcomes. Irvine, California–based Edwards presented the data during the late-breaking clinical science session at the 33rd Transcatheter Cardiovascular Therapeutics (TCT), according to a news release. The study evaluated 132 patients (56 patients with six-month follow-up) […]

Filed Under: Cardiac Implants, Cardiovascular, Catheters, Clinical Trials, Featured, Replacement Heart Valves, Structural Heart Tagged With: Edwards Lifesciences

Sapien 3 TAVR offers improved outcomes, reduced cost, Edwards Lifesciences says

November 5, 2021 By Sean Whooley

Edwards Lifesciences (NYSE:EW) today touted a cost-effectiveness analysis that supports transcatheter aortic valve replacement (TAVR) with the Sapien 3. Irvine, California-based Edwards presented data from the Partner 3 trial during the late-breaking clinical trials at the 33rd Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation. According to a news release, […]

Filed Under: Cardiac Implants, Cardiovascular, Catheters, Clinical Trials, Featured, Replacement Heart Valves, Structural Heart Tagged With: Edwards Lifesciences, tavr

Edwards Lifesciences reports mixed Q3 financial results

October 28, 2021 By Jim Hammerand

Edwards Lifesciences (NYSE: EW) reported third-quarter financial results that exceeded Wall Street’s expectations on profits but narrowly missed on sales. The Irvine, California–based cardio device company yesterday evening reported earnings of $340.1 million (or 54¢ per share) off sales of $1.31 billion. That’s a 4.6% increase from Q3 2020’s earnings of $325.2 million (52¢ per share) […]

Filed Under: Business/Financial News, Cardiovascular, Featured, MassDevice Earnings Roundup, News Well, Replacement Heart Valves, Structural Heart, Structural Heart, Wall Street Beat Tagged With: Edwards Lifesciences

3 pitfalls to consider when creating catheter delivery systems

August 25, 2021 By Danielle Kirsh

Multiple components go into a catheter delivery system, with several ways to combine them. An Edwards Lifesciences senior R&D director goes over potential pitfalls. A catheter is a tube that can deliver devices or pharmaceuticals into the body. It is also commonly used for diagnostic purposes. A catheter has a hub or a handle on […]

Filed Under: Cardiovascular, Catheters, Featured Tagged With: Edwards Lifesciences

MedTech 100 roundup: Industry climbs with earnings season in full swing

August 2, 2021 By Sean Whooley

Better-than-expected quarterly earnings are providing a further boost to medtech industry stocks. MassDevice‘s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished last week (July 30) at 118.86 points. Two weeks ago aside — when the index shot up to 145.88 points and quickly tumbled down — this mark […]

Filed Under: Business/Financial News, Featured, Funding Roundup, Initial Public Offering (IPO), MassDevice Earnings Roundup, Mergers & Acquisitions, Wall Street Beat Tagged With: 3m, Baxter, BD, Boston Scientific, coronavirus, COVID-19, Dexcom, Edwards Lifesciences, GE Healthcare, Hillrom, Hologic, MedTech 100 Index, Pfizer, Philips, Smith+Nephew, Stryker, Tenaya Therapeutics

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Interim pages omitted …
  • Go to page 50
  • Go to Next Page »

Primary Sidebar

DeviceTalks Weekly

July 1, 2022
Boston Scientific CEO Mike Mahoney on building a corporate culture that drives high growth results
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS